Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: Position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group

H. Quach, D. Joshua, J. Ho, J. Szer, A. Spencer, S.J. Harrison, P. Mollee, A.W. Roberts, N. Horvath, D. Talulikar, B. To, A. Zannettino, R. Brown, L. Catley, B. Augustson, W. Jaksic, J. Gibson, H.M. Prince

Research output: Contribution to journalArticleResearchpeer-review

12 Citations (Scopus)


The survival of patients with multiple myeloma (MM) has improved substantially since the introduction in the late 1980s of high-dose chemotherapy (HDT) supported by autologous stem cell transplantation (ASCT). Further improvements have been observed following the availability of immunomodulatory drugs (IMiD) such as thalidomide and lenalidomide, and the proteasome inhibitor, bortezomib. Here, we summarise the recommendations of the Medical Scientific Advisory Group to the Myeloma Foundation of Australia for patients considered suitable for HDT + ASCT as part of initial therapy. These recommendations incorporate the various phases of treatment: induction, HDT conditioning and maintenance therapy.

Original languageEnglish
Pages (from-to)94-105
Number of pages12
JournalInternal Medicine Journal
Issue number1
Publication statusPublished - Jan 2015
Externally publishedYes


  • Multiple myeloma
  • Stem cell transplant
  • Therapy

Cite this